FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia
Links shared publicly online about this topic.
- 1,362total visits
FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia
View full resource at drugs.com
Tags: Leukemia, Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma Medication, Rheumatoid Arthritis Medication, FDA, Rituxan, MabThera
Most Recently Shared on February 22, 2010 at 11:41 pm By:
FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia - http://bit.ly/960vQR
UPDATE 1-US approves Roche's Rituxan cancer drug for CLL | Reuters
reuters.com — “* FDA approves Rituxan for most common adult leukemia * Approved as first-line CLL treatment * Can also be used after other drugs fail * Had 2009 sales of $5.6 bln NEW YORK, Feb 18 (Reuters) -” View full resource at reuters.com
Most Recently Shared on February 20, 2010 at 3:00 pm By:
FDA approves use of Rituxan for chronic lymphocytic leukemia. http://www.reuters.com/article/idUSN1820063720100218
Rituxan approved for chronic lymphocytic leukemia - MPR
empr.com — “The FDA has approved Rituxan (rituximab, from Genentech) in combination with fludarabine and cyclophosphamide (FC) for patients with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL).” View full resource at empr.com
Most Recently Shared on February 19, 2010 at 3:50 pm By:
MPR News: Rituxan approved for chronic lymphocytic leukemia: The FDA has approved Rituxan (rituximab, from Genente... http://bit.ly/deIPpG
FDA Approves Arzerra (ofatumumab) for Chronic Lymphocytic Leukemia
drugs.com — “Arzerra (ofatumumab) is used to treat chronic lymphocytic leukemia. Includes Arzerra side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on October 27, 2009 at 9:55 pm By:
FDA Approves Arzerra (ofatumumab) for Chronic Lymphocytic Leukemia - http://bit.ly/yxvVM
Supplemental BLAs submitted for Rituxan for chronic lymphocytic leukemia - MPR
empr.com — “Genentech and Biogen Idec announced that they submitted two supplemental Biologics License Applications (sBLAs), along with a priority review request, to the FDA for Rituxan (rituximab) plus standard (fludarabine and cyclophosphamide) chemotherapy for patients with previously untreated or treated chronic lymphocytic leukemia (CLL).” View full resource at empr.com
Most Recently Shared on May 20, 2009 at 9:30 pm By:
MPR News: Supplemental BLAs submitted for Rituxan for chronic lymphocytic leukemia: Genentech and Bioge.. http://tinyurl.com/posl4z
Advertisement
